Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial

摘要

This is the first report on the clinical use of a new derivative of enrofloxacin (enrofloxacin HCl-2H2O or enro-C) for the treatment of canine unresponsive deep-pyoderma (UDCP), utilizing a dual scheme, i.e., 10 mg/kg/day in capsules, plus the topical administration of enro-C, prepared as an 0.5% alginate gel, thrice per day. Fifty-five cases of UDCP were treated successfully in a one-year study. Mean days of treatment were 8 to 12, for either severe or very severe cases, respectively. Complete success was recorded and no recurrences after a two-month clinical follow up were registered. It is here proposed that the dual treatment, the potency of enro-C and the theoretically high concentrations of the active principle in the lesions may explain these findings. Further research is needed to define the bacteriological status of the pathogens found, and the impact of this treatment in bacterial resistance.